Skip to main content

Table 1 Characteristics of patients from the University of Chicago

From: Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation

Clinical and PET Parameters

Number of patients

Percentage

Gender

ā€ƒMale

47

43%

ā€ƒFemale

63

57%

Race

ā€ƒCaucasian

47

43%

ā€ƒAfrican American

60

55%

ā€ƒAsian

3

3%

Treatment

ā€ƒSurgically

24

22%

ā€ƒNon-surgically

76

69%

ā€ƒNone

10

9%

Histological subtype

ā€ƒAdenocarcinoma

45

41%

ā€ƒSquamous cell

35

32%

ā€ƒOther typesa

30

27%

Age (Median and range, years)

67.3(31.4ā€“83.9)

Ā 

ā€ƒ>65

44

40%

ā€ƒ<65

66

60%

MTVwb (Median and range, ml)

85.6(3.2ā€“1261.4)

Ā 

TLGwb (Median and range, ml)

485.5(12.1ā€“4921.0)

Ā 

SUVmaxwb (Median and range)

13.07(3.5ā€“42.9)

Ā 
  1. MTVwb whole-body metabolic tumor volume, SUVmaxwb whole-body maximum standardized uptake value, TLGwb whole-body total lesion glycolysis
  2. aOther histological subtypes including large cell (nĀ =Ā 7), NSCLC not otherwise specified (nĀ =Ā 21) and neuroendocrine tumor (nĀ =Ā 2)